| pubmed-article:1851388 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1851388 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1851388 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:1851388 | lifeskim:mentions | umls-concept:C0002475 | lld:lifeskim |
| pubmed-article:1851388 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:1851388 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:1851388 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:1851388 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1851388 | pubmed:dateCreated | 1991-6-11 | lld:pubmed |
| pubmed-article:1851388 | pubmed:abstractText | Sixty-five patients (20 patients who had had prior radiotherapy and 45 patients who had not had prior radiotherapy) were entered into a study evaluating escalating doses of etoposide and mitomycin in the treatment of non-small-cell lung cancer (NSCLC). Twenty-two percent of patients who had not received prior radiotherapy responded to the chemotherapy, compared with 5% of patients who had received prior radiotherapy. The best response rate and median survival time was 30% and 31.9 weeks, respectively, seen in three of 10 patients receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3. The major toxicity was hematologic--mainly leukopenia, in 59% of patients who had had no prior radiation therapy and were receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 150 mg/M2 i.v. days 1-3 (grade 3 and 4 hematologic toxicity). The mitomycin-etoposide drug combination has some activity in patients with NSCLC who have not received prior radiotherapy. The recommended starting dose is mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3, administered every 4 weeks. | lld:pubmed |
| pubmed-article:1851388 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1851388 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1851388 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1851388 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1851388 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1851388 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1851388 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:1851388 | pubmed:issn | 0277-3732 | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:LosadaMM | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:HarrisC LCL | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:EttingerD SDS | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:ComisR LRL | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:BitranJ DJD | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:LangerC JCJ | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:KellerJ HJH | lld:pubmed |
| pubmed-article:1851388 | pubmed:author | pubmed-author:HarwoodK VKV | lld:pubmed |
| pubmed-article:1851388 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1851388 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:1851388 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1851388 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1851388 | pubmed:pagination | 127-32 | lld:pubmed |
| pubmed-article:1851388 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:meshHeading | pubmed-meshheading:1851388-... | lld:pubmed |
| pubmed-article:1851388 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1851388 | pubmed:articleTitle | Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation. | lld:pubmed |
| pubmed-article:1851388 | pubmed:affiliation | Johns Hopkins Oncology Center, Baltimore, MD 21205. | lld:pubmed |
| pubmed-article:1851388 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1851388 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
